Europe and the UK are overhauling healthcare AI oversight, shifting from static approvals to continuous lifecycle monitoring to ease compliance burdens under the EU AI Act and Medical Device Regulations. Concurrently, AI captured 48% of European health venture capital in 2026, driving major funding rounds and acquisitions like GE HealthCare's $945 million deal for SOFIE Biosciences. Meanwhile, cross-border clinical pilots, sovereign compute initiatives, and digital twins are